Pfizer Stock News

Pfizer is expected to submit a request to the FDA as soon as tomorrow for emergency-use authorization.

COVID vaccines for children younger than 5 could be available as soon as the end of February under a plan that would lead to the authorization of a two-shot regimen.

U.S. regulators are urging drugmaker Pfizer to apply for emergency authorization for a two-dose regimen of its COVID-19 vaccine for children 6 months to 5 years old

The Pfizer/BioNTech COVID-19 vaccine could be authorized for children under the age of five years old by the end of February, The Washington Post reports.

Shares of Novavax Inc. rallied 10.0% in trading on Monday after the company said it filed for authorization of its experimental COVID-19 shot in the U.S. Novavax''s COVID-19 vaccine candidate is protein-based, meaning it''s a different type of vaccine than the mRNA shots developed by BioNTech SE /Pfizer Inc. and Moderna Inc. or the Johnson & Johnson viral vector vaccine. Novavax said it is seeking authorization for its two-dose vaccine in adults, based on two clinical studies. One Phase 3 trial assessing the vaccine in about 15,000 adults in the U.K. reported an 89.7% efficacy rate against infection with the virus, according to research published in the New England Journal of Medicine in September. A second trial that enrolled about 30,000 adults in the U.S. and Mexico found that shots produced an efficacy rate of 92.6% against any variants of concern or interest. That study was also published in the New England Journal of Medicine, in December. Some of the vaccine''s side effects include headache, pain at the injection site, and fatigue.

The drugmaker is throwing in the towel on a once-promising pipeline candidate.

The Pfizer vaccine was fully approved in August.

A vial of the Moderna COVID-19 vaccine is displayed on a counter at a pharmacy in Portland, Ore., Monday, Dec. 27, 2021. The FDA has full approved the Moderna COVID-19 vaccine. | Jenny Kane, Associated Press What did we learn about Modernas COVID-19 vaccine? The Food and Drug Administration Monday approved a second COVID-19 vaccine the Moderna COVID-19 vaccine , which will be marketed as Spikevax. What happened: The FDA said Modernas vaccine, called Spikevac, met the rigorous standards for safety, effectiveness and manufacturing quality required for approval. The vaccine has been approved for emergency use authorization for those 18 years old and up. Quote: The FDAs approval of Spikevax is a significant step in the fight against the COVID-19 pandemic, marking the second vaccine approved to prevent COVID-19. The public can be assured that Spikevax meets the FDAs high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States, said Dr.

Rickards Slams Big Pharma''s Siege Of America Authored by James Rickards via DailyReckoning.com, Remember this time last year when the vax bandwagon really got rolling? The vax had been announced in November 2020 and was fast-tracked through the approval process (on an experimental basis at the time). But it took a while to get to doses shipped and distributed and for people to become aware of where they could get it. That played out over December 2020, but by January 2021, the effort was in full swing. The first thing those getting jabbed learned was they would have to return in a few weeks for the second dose. That was understood and widely accepted, although the Janssen vaccine is different and only requires one shot. Janssen is not nearly as available as the mRNA vaccines from Pfizer and Moderna. The bandwagon continued through 2021 to the point that about 70% of the U.S. population is now fully vaccinated. So Much for the Pandemic of the Unvaccinated But by September 2021, doubts arose about the efficacy of the vaccines.

Pfizer backed out of a deal to co-develop an Ionis Pharmaceuticals heart-disease drug on Monday, leading IONS stock to crumble.

Pfizer Inc (NYSE: PFE ) and Ionis Pharmaceuticals Inc (NASDAQ: IONS ) will discontinue the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy. A little over two years after Pfizer paid Ionis $250 million cash to in-license rights to vupanorsen (AKCEA-ANGPTL3-LRx), now the pharma giant has decided to ax late-stage Full story available on Benzinga.com

Ionis Pharmaceuticals (IONS) down 9.2% premarket after discontinuing the Pfizer (PFE)-led clinical development program for vupanorsen (PF-07285557), an investigational antisense

Alex Therapeutics and Pfizer (PFE) have joined forces to provide evidence based, clinically validated and personalized digital therapies to patients

"Irresponsible People Are Spreading Lies" - Joni Mitchell Removes Music From Spotify "In Solidarity" With Neil Young Another popular Canadian-born classic rock musician has decided to pull her music from Spotify in solidarity with Neil Young, whose label pulled his music from the streaming giant in protest over its deal with Joe Rogan. Popular folk musician Joni Mitchell - who, like Young, was in her hayday back in the 1970s but nevertheless maintains an audience among the young people of today (she''s particularly popular with a certain demographic: gay women) - announced her decision to pull her music from Spotify in a statement on her website. "Ive decided to remove all my music from Spotify. Irresponsible people are spreading lies that are costing people their lives. I stand in solidarity with Neil Young and the global scientific and medical communities on this issue," she said. As of Saturday morning in New York, most of Mitchell''s catalogue was still available on the app; Young''s had been removed earlier in the week after he sent the company a letter declaring that the service could have "Neil Young or Joe Rogan.

Even the CEOs of Pfizer and Moderna, who were leaning toward fourth doses, have eased off their rhetoric. The data just isn''t there, scientists say.